Table 3.
Study | Study objective, (intervention/exposure and outcomes) | Study design, data source | Study population, study setting, time period | Results | Quality assessment, funding source |
---|---|---|---|---|---|
Dharmarajan et al. (2006) [27] | To evaluate the decision whether or not to anticoagulate among physicians in practice and in various levels of training (residents and fellows) for a specific, yet not unusual, case scenario in the nursing home |
Design: cross-sectional study Data source: survey questionnaire based on an actual case from an LTC facility. The subject of the survey was an 87-year-old female LTC facility resident with dementia, AF, and history of hip fracture who suffered a recent fall without fracture |
Population: 107 completed surveys were returned from 49 residents, 20 fellows, and 38 attending physicians Setting: a university teaching hospital in the Bronx, NY (US) Time period: survey dates not specified |
The majority of physicians (85%) thought that long-term anticoagulation therapy was not indicated in the case patient. However, most (88%) said they would provide an antiplatelet agent (78% aspirin, 20% clopidogrel). The most cited reasons for not providing anticoagulation were risk of falls (98%), dementia (40%), and short life expectancy (32%). 92% of respondents said the patient was a candidate for short-term anticoagulation therapy. Responses to the questions were similar for all physicians (or faculty) irrespective of level of training or years in practice |
Quality assessment for observational studies: 1) Unbiased selection of the cohort? Cannot be determined; cohort selection details not provided; non-response rate not disclosed 2) Selection minimizes baseline differences in prognostic factors? Cannot be determined 3) Sample size calculated/5% difference? No 4) Adequate description of the cohort? No; details of cohort other than practice specialty were not provided 5) Validated method for ascertaining exposure? No; reliability concern since limited to 1 case study; content validity of case study not described 6) Validated method for ascertaining clinical outcomes? No; validation assessment of response choices not performed 7) Outcome assessment blind to exposure? NA 8) Adequate follow-up period? Yes; cross-sectional 9) Completeness of follow-up? Yes 10) Analysis controls for confounding? Partial; cross-tabulations performed on responses by specialty 11) Analytic methods appropriate? Yes Funding: Geriatric Medicine Fellowship program |
Harrold et al. (2002) [28] | To examine physician attitudes regarding the use of specialized anticoagulation services in the LTC setting |
Design: cross-sectional study Data source: survey questionnaire |
Population: 245 physicians asked to participate in the survey; 114 (47%) responded. 91 reported that they currently cared for residents in LTC facilities and thus completed the questionnaire Setting: 21 LTC facilities in Connecticut (US) Time period: Nov 1999 - Jan 2000 |
The majority of respondents agreed or strongly agreed that an anticoagulation service would reduce the workload on physicians (76%), and increase the percent of time that nursing home residents on warfarin are maintained in the target therapeutic range (54%). 53% disagreed or strongly disagreed with statements suggesting that this service would reduce the risk of warfarin-related bleeding. 45% of respondents agreed with a statement that this service would intrude on physician decision-making. 53% of the respondents said they might use an anticoagulation service for managing their LTC patients on warfarin. The most desirable aspects of an anticoagulation service were surveillance for drug interactions (65%), scheduling of laboratory tests (48%), management of warfarin dosing (45%), and risk assessment for bleeding (40%). The most frequently cited challenges to managing warfarin therapy in the nursing home setting were dealing with medications that interact with warfarin (59%), keeping patients within target therapeutic range (53%), and making dosage adjustments (30%) |
Quality assessment for observational studies: 1) Unbiased selection of the cohort? Yes 2) Selection minimizes baseline differences in prognostic factors? Yes; performed analysis of non-responders 3) Sample size calculated/5% difference? No 4) Adequate description of the cohort? Yes 5) Validated method for ascertaining exposure? No; minimal description of anticoagulation services provided 6) Validated method for ascertaining clinical outcomes? Validation of new questionnaire not reported 7) Outcome assessment blind to exposure? NA 8) Adequate follow-up period? Yes; cross-sectional 9) Completeness of follow-up? Yes 10) Analysis controls for confounding? No; cross tabulation with subject attributes not performed 11) Analytic methods appropriate? No; statistical error (CIs) reported in only some findings Funding: Centers for Medicare and Medicaid Services, Department of Health and Human Services; AHRQ |
Monette et al. (1997) [29] | To assess the knowledge and attitudes of physicians regarding the use of warfarin for stroke prevention in patients with AF in LTC facilities |
Design: cross-sectional study Data source: survey questionnaire of 2 clinical scenarios with substantial contrasts in patient characteristics: 1) 94-year old male resident with chronic AF, ischemic heart disease, CHF and osteoarthritis, no history of falls, independent in activities of daily living; 2) 80-year old female with recent stroke with resulting hemiplegia and dysarthria, having chronic AF, CHF, CAD, hypertension, diabetes, and chronic renal insufficiency, with cognitive deficits and entirely nonambulatory |
Population: 269 physicians were asked to participate in the survey; 182 (67.7%) completed the questionnaire Setting: 30 LTC facilities located in New England, Quebec, and Ontario (US and Canada) Time period: Feb 1995 to Jul 1995 |
Only 47% of respondents indicated that the benefits of warfarin greatly outweigh the risks in this setting; the remainder of physicians indicated that benefits only slightly outweigh the risks (34%) or that risks outweigh benefits (19%). The most frequently cited contraindications to warfarin use were: excessive risk of falls (71%), history of GI bleeding (71%), history of non-CNS bleeding (36%), and history of cerebrovascular hemorrhage (25%). Among the 164 physicians who reported using the INR to monitor warfarin therapy, 27% indicated a target range with a lower limit < 2.0, 71% indicated a target range between 2.0 and 3.0, and 2% indicated an upper limit > 3.0. Among respondents who answered questions about the clinical scenarios, estimates of the risk of stroke without warfarin therapy and the risk of intracranial hemorrhage with therapy varied widely |
Quality assessment for observational studies: 1) Unbiased selection of the cohort? Yes 2) Selection minimizes baseline differences in prognostic factors? No; analysis of non-responders was not performed 3) Sample size calculated/5% difference? No 4) Adequate description of the cohort? Yes 5) Validated method for ascertaining exposure? Yes; conducted pre-testing to establish content validity 6) Validated method for ascertaining clinical outcomes? No further assessment validity conducted for new questionnaire 7) Outcome assessment blind to exposure? NA 8) Adequate follow-up period? Yes; cross-sectional 9) Completeness of follow-up? Yes 10) Analysis controls for confounding? Yes 11) Analytic methods appropriate? No; statistical error (CIs) reported in only some findings Funding: Dupont Pharma |
AF, atrial fibrillation; AHRQ, Agency for Healthcare Research and Quality; CAD, coronary artery disease; CHF, congestive heart failure; CI confidence interval; CNS, central nervous system; GI, gastrointestinal; INR, international normalized ratio; LTC, long-term care; NA not available.